Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
North America Flexible Endoscopic Surgery Robot Market Size & Share 2026-2035
Report ID: GMI15088
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
North America Flexible Endoscopic Surgery Robot Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
North America Flexible Endoscopic Surgery Robot Market Size
The North America flexible endoscopic surgery robot market was valued at USD 657.3 million in 2025, is projected to reach USD 742 million in 2026, and is expected to expand at a CAGR of 11.7% from 2026 to 2035, reaching USD 1.98 billion by 2035.
North America Flexible Endoscopic Surgery Robot Market Key Takeaways
Market Leader: Intuitive Surgical led with over 58% market share in 2025.
Leading Players: Top 5 players in this market include Intuitive Surgical, J&J / Auris Health, Noah Medical, which collectively held a market share of 89% in 2025.
The North America market is moving from an early platform-placement cycle toward a more utilization-led revenue model. Established bronchoscopy programs are increasing procedure throughput and recurring purchases of accessories and service, while advances in navigation software and the prospect of GI commercialization broaden the market's longer-term clinical opportunity.
The market covers robotic systems, procedure-specific single-use accessories, software and AI navigation modules, and service contracts used in minimally invasive flexible endoscopic procedures through natural body orifices in the United States and Canada. It includes robotic bronchoscopy, robotic ureteroscopy and renal access, and robotically assisted GI endoscopic surgery, while excluding rigid robotic surgical systems, standalone non-robotic endoscopy equipment, diagnostic imaging modalities, and reprocessing equipment.
GMI Analyst View
Based on GMI's primary research and consultations with hospital capital planning teams, surgical-robotics procurement specialists, and institutional adoption advisors, we estimate the global flexible endoscopic surgery robot market at approximately USD 1.09 billion in 2025. North America's leadership reflects its concentration of commercial platform launches, established reimbursement pathways, and the depth of hospital and ambulatory surgical center infrastructure supporting clinical adoption.
North America Flexible Endoscopic Surgery Robot Market Trends, Growth Drivers & GMI Forecast Outlook
Near-term demand rests on established respiratory procedure volumes and installed-platform utilization, while mid-forecast performance depends on whether GI robotic systems obtain timely authorization, coverage, and clinical adoption. AI-enabled navigation and outpatient migration can expand the addressable facility base, but reimbursement and regulatory sequencing remain decisive constraints.
Key Drivers
*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*
Broader lung cancer screening eligibility matters commercially because it increases the flow of peripheral pulmonary nodules requiring tissue diagnosis. Robotic bronchoscopy is positioned at the point where screening converts into an interventional procedure, making respiratory utilization less dependent on the cadence of new capital purchases than on the durability of diagnostic pathways.
The ASC opportunity is more selective than a simple migration from hospital outpatient care. Centers need concentrated procedural volume, specialized clinical staffing, and a reimbursement model that can support the capital commitment. Where those conditions align, robotic ureteroscopy and bronchoscopy can generate recurring instrument demand and raise the strategic value of installed systems.
AI-enhanced navigation addresses a practical adoption barrier: clinicians must confidently reach and verify targets despite intraoperative anatomical variation. By embedding image guidance more deeply in the workflow, suppliers can make robotic bronchoscopy more attainable for community programs, where procedural consistency and staff efficiency often weigh as heavily as technical novelty.
Key Restraints
*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*
Canadian market entry involves more than a formal review standard. Manufacturers must navigate application preparation, possible deficiency responses, and provincial procurement processes after authorization. That sequence favors suppliers with established clinical evidence, local support capabilities, and the patience to work through public-sector capital planning cycles.
The ASC reimbursement issue is a capital-allocation problem rather than a lack of clinical interest. When navigation-related economics are weaker in an outpatient setting, standalone centers must rely on procedure volume and bundled reimbursement to justify a robotic program. This limits early deployment to facilities with sufficient scale and strategic specialization.
GI robotics faces an unusually sequential pathway from investigational development to routine commercial revenue. Regulatory authorization alone does not establish payer confidence, clinician training capacity, or a reliable referral base. The resulting timing risk is material because GI is expected to diversify the market beyond the more mature respiratory and urology use cases.
GMI Analyst View
We view the market's central tension as the contrast between a visible respiratory demand base and a GI growth option whose commercial timing remains uncertain. The installed bronchoscopy ecosystem can sustain recurring revenue, but the next phase of expansion will depend on translating regulatory progress into reimbursed, repeatable GI procedures rather than simply introducing new platforms.
North America Flexible Endoscopic Surgery Robot Market Segment Analysis
By Category
The Therapeutic category in the North America Flexible Endoscopic Surgery Robot Market generated USD 425.9 million in 2025 and is projected to expand at a 12.5% CAGR (2026–2035). Therapeutic demand is broadening as robotic flexible endoscopy is applied to lesion treatment, stone management, resectional procedures, and other interventions that require controlled access and instrument precision. Its momentum reflects a shift in the value proposition from navigation and diagnosis alone toward platforms that can participate in higher-acuity procedural workflows.
The Diagnostic category is projected to reach USD 600.9 million by 2035 and represented 35.2% of market revenue in 2025. Diagnostic procedures remain the commercial foundation of the category because lung nodule localization and tissue acquisition precede treatment decisions. Continued screening activity, clinical familiarity with navigated bronchoscopy, and the recurring-use profile of accessories should preserve a substantial diagnostic revenue stream even as therapeutic use expands faster.
By Application
Urology
Urology generated USD 217.4 million in 2025 and is expected to grow at a 12.4% CAGR (2026–2035). The application benefits from established minimally invasive treatment pathways for stone disease and other upper-tract indications. Its relative commercial stability gives providers a practical route to expand robotic use beyond pulmonary programs, particularly where procedure scheduling and physician expertise support outpatient delivery.
Respiratory
Respiratory generated USD 274.2 million in 2025 and is expected to account for 35.9% of market revenue in 2035. Respiratory remains the largest established application because hospitals have already built the interventional pulmonology teams, imaging workflows, and reimbursement processes needed to operate robotic bronchoscopy programs. The next competitive phase will hinge on navigation accuracy, workflow integration, and the ability to monetize a growing installed base through instruments and service.
GI (Gastrointestinal)
GI is projected to reach USD 473.7 million by 2035 and is expected to expand at a 13.6% CAGR (2026–2035). GI represents the market's most important expansion frontier, but it will not scale solely through device availability. Adoption requires specialist endoscopist training, clinical evidence, hospital workflow integration, and payer confidence in the procedural value of robotic assistance for ESD, EMR, and related interventions.
Other Applications
Other applications are projected to reach USD 100.3 million by 2035 and represented 5.1% of market revenue in 2025. This group includes emerging endoluminal and niche therapeutic uses that can create option value for platform suppliers without yet reshaping the market's core demand structure. Their importance lies in extending system utility across a wider clinical portfolio and improving the economics of installed equipment.
By End Use
Hospitals & Clinics
Hospitals & Clinics generated USD 464.9 million in 2025 and are projected to represent 58.7% of market revenue in 2035. Hospitals remain the principal setting for capital-intensive robotic programs because they can marshal multidisciplinary clinical teams, advanced imaging support, and institutional procurement resources. They are also the most likely initial sites for complex GI procedures and early adoption of next-generation navigation software.
ASCs
ASCs are projected to reach USD 718.2 million by 2035 and are expected to grow at a 16.4% CAGR (2026–2035). ASC adoption is being shaped by the intersection of outpatient procedure economics, physician ownership models, and specialization. The channel's expansion will be strongest where centers can aggregate sufficient bronchoscopy or urology volume, while reimbursement treatment of navigation services will determine how quickly adoption reaches beyond high-volume operators.
Other End Use
Other end users represented 5.2% of market revenue in 2025 and are projected to reach USD 102.0 million by 2035. Government facilities, military health systems, research institutions, and training centers play a narrower but useful role in validating workflows and developing clinical expertise. Their procurement patterns are less likely to drive broad volume growth, yet their influence can support education and evidence generation for newer applications.
GMI Analyst View
We see segmentation as a sequencing story rather than a collection of independent growth pockets. Respiratory supports current utilization, urology offers a commercially familiar extension, and GI creates the largest longer-term expansion opportunity. Care-setting migration will matter most once new applications have sufficiently standardized their training, reimbursement, and operating models.
North America Flexible Endoscopic Surgery Robot Market Regional Analysis
United States Flexible Endoscopic Surgery Robot Market Analysis
In the North America Flexible Endoscopic Surgery Robot Market, the U.S. Flexible Endoscopic Surgery Robot Market generated USD 609.8 million in 2025 and is projected to reach USD 1.85 billion by 2035.
The U.S. combines early regulatory access, established procedural reimbursement, a large hospital base, and a developed outpatient ecosystem. These conditions shorten the path from platform authorization to physician training, clinical utilization, and recurring instrument demand. U.S. academic centers are also likely to be the first commercial sites for newly cleared GI robotic systems.
The market is entering a period in which installed-platform productivity becomes more important than the initial rollout of bronchoscopy systems. Suppliers that can improve navigation, expand procedure indications, and secure favorable hospital and ASC purchasing pathways will be better positioned to convert early adoption into durable account relationships.
Canada Flexible Endoscopic Surgery Robot Market Analysis
The Canada Flexible Endoscopic Surgery Robot Market generated USD 47.5 million in 2025 and is expected to grow at an 11.0% CAGR (2026–2035). Canada's market follows a different adoption pattern, led by academic hospital programs and mediated by public-sector capital planning. Regulatory sequencing and provincial purchasing processes tend to extend the commercialization timeline for complex robotic systems, particularly when clinical and budgetary decisions must advance through separate institutional channels.
Growth will remain concentrated in hospital bronchoscopy programs before GI applications become more broadly accessible. The smaller outpatient surgery ecosystem also limits the immediate transferability of the U.S. ASC model, leaving Canadian demand more dependent on large institutional accounts and carefully staged technology adoption.
GMI Analyst View
We expect the United States and Canada to remain structurally differentiated throughout the forecast horizon. The United States will set the pace for new platform generations, application diversification, and outpatient deployment, while Canada's growth will be steadier and more institutionally concentrated. The key Canadian upside lies in whether funding and procurement pathways evolve alongside clinical evidence.
North America Flexible Endoscopic Surgery Robot Market Share & Competitive Landscape
The North America Flexible Endoscopic Surgery Robot Market share structure is anchored in robotic bronchoscopy, where established suppliers benefit from installed platforms, physician training networks, accessory ecosystems, and hospital contracting relationships. Competition is becoming more intense as AI-enabled navigation raises performance expectations, newer bronchoscopy systems build clinical evidence, and GI-focused entrants seek to establish commercial relevance.
Intuitive Surgical (Ion) held approximately 58% of market revenue in 2025. Its position is supported by the Ion platform's installed base, shape-sensing navigation, and recurring accessory and service model.
Intuitive Surgical's competitive advantage lies in converting installed-platform familiarity into retention during renewal and expansion decisions. Its AI and advanced imaging updates strengthen the platform's relevance where hospital systems increasingly evaluate procedural confidence, workflow efficiency, and the ability to keep pace with evolving imaging requirements. Intuitive announced FDA clearance of enhanced AI and imaging capabilities for Ion in October 2025 [5]Intuitive Surgical, Inc. “Intuitive Expands AI and Advanced Imaging Integration in Ion Endoluminal System.” isrg.intuitive.com.
J&J / Auris Health (Monarch) held approximately 24% of market revenue in 2025. Monarch remains a well-established competitor in robotic bronchoscopy with an installed base and a growing technology position across pulmonary and urological workflows.
J&J's strategic challenge is to preserve its role in large health-system accounts as navigation capabilities become a more explicit procurement criterion. Its ability to pair clinical evidence, imaging integration, and commercial support will be central to sustaining relevance as customers assess both incumbent platforms and newer alternatives.
Noah Medical (Galaxy) held approximately 7% of market revenue in 2025. The company's position reflects rapid uptake of the Galaxy System in hospital bronchoscopy programs.
Galaxy's importance extends beyond its current share because it demonstrates that newer suppliers can gain consideration where image integration and procedural verification address unmet workflow needs. Noah Medical reported that the Galaxy System surpassed 5,000 procedures in March 2025, underscoring the growing commercial footprint of its platform [7]Noah Medical. “Noah Medical’s Galaxy System Surpasses 5,000 Procedures, Marking a New Era in Robotic-Assisted Bronchoscopy.” noahmed.com.
Boston Scientific has a strategically relevant position in GI endoscopy through its physician relationships and established portfolio of tools used in EMR and ESD procedures.
Although it is not currently defined by a direct robotic flexible endoscopy platform position, Boston Scientific has access to the procedural settings and clinician networks that could matter as robotic GI workflows mature. Its relevance rests on whether it chooses to extend existing endoscopic capabilities through internal development, collaboration, or adjacent technology participation.
Olympus Corporation of the Americas is positioned to participate in robotic GI endoscopy through its distribution relationship with EndoRobotics for the ROBOPERA system.
Olympus can leverage its established endoscopy sales and service infrastructure as robotic GI tools move from early clinical use toward broader hospital adoption. The company and EndoRobotics announced an exclusive global distribution agreement for ROBOPERA in 2026, bringing the system into the Olympus EndoTherapy portfolio [6]EndoRobotics Co., Ltd. “Company Overview — Milestones.” endorobo.com.
Medivators (Cantel Medical / Steris) participates indirectly through endoscope reprocessing, maintenance, and infection-control offerings that support the operational environment for robotic endoscopy programs.
Its role is tied to serviceability, compliance, and procedure-room readiness rather than direct competition in robotic capital equipment. As procedure volumes rise, these operational requirements remain relevant to hospital and ambulatory customers managing complex endoscopy fleets.
Recent Industry Developments
Intuitive Surgical receives FDA clearance for AI-integrated Ion software — October 2025. Intuitive Surgical announced FDA clearance for software enhancements that integrate AI and advanced imaging into the Ion endoluminal system. The update is designed to improve intraoperative navigation through real-time correction of CT-to-body divergence and expanded imaging integration [5]Intuitive Surgical, Inc. “Intuitive Expands AI and Advanced Imaging Integration in Ion Endoluminal System.” isrg.intuitive.com.
Olympus and EndoRobotics announce ROBOPERA distribution agreement — May 2026. Olympus and EndoRobotics announced an exclusive global distribution agreement for ROBOPERA, a robotic-assisted tool for GI tissue manipulation in ESD and mucosal resection workflows. The agreement brings the system into the Olympus EndoTherapy portfolio and gives the technology access to an established endoscopy commercial channel [6]EndoRobotics Co., Ltd. “Company Overview — Milestones.” endorobo.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →